Table 2.
General characteristics of the study population with nonfibrocystic bronchiectasis
| Variables | Overall cohort | Alive | Died | P value |
|---|---|---|---|---|
| Number of patients, n | 120 | 107 | 13 | |
| Female, n (%) | 84 (70.0) | 77 (72.0) | 7 (53.8) | .305 |
| Age, year, median (IQR) | 59.50 (19.25) | 59.0 (18.50) | 71.0 (23.00) | .106 |
| BMI, kg/m², median (IQR) | 23.64 (6.27) | 24.02 (6.07) | 20.66 (6.06) | .014 |
| Comorbidity, n (%) | ||||
| Without comorbidities | 24 (20.0) | 21 (19.6) | 3 (23.1) | .188 |
| With comorbidities | 35 (29.2) | 34 (31.8) | 1 (7.7) | |
| ≥ 2 comorbidities | 61 (50.8) | 52 (48.6) | 9 (69.2) | |
| Systemic arterial hypertension, n (%) | 57 (47.5) | 49 (45.8) | 8 (61.5) | .436 |
| Cardiovascular disease, n (%) | 11 (9.2) | 11 (10.3) | 0 (0.0) | .481 |
| Diabetes mellitus, n (%) | 19 (15.8) | 15 (14.0) | 4 (30.8) | .246 |
| GERD, n (%) | 11 (9.2) | 11 (10.3) | 0 (0.0) | .481 |
| Cardiovascular disease, n (%) | 14 (11.7) | 12 (11.2) | 2 (15.4) | 1 |
| Neoplastic disease, n (%) | 9 (7.5) | 7 (6.5) | 2 (15.4) | .558 |
| Hypothyroidism, n (%) | 4 (3.3) | 2 (1.9) | 2 (15.4) | .081 |
| COPD, n (%) | 33 (27.5) | 28 (26.2) | 5 (38.5) | .543 |
| Asthma, n (%) | 24 (20.0) | 23 (21.5) | 1 (7.7) | .419 |
| Previous tuberculosis, n (%) | 68 (56.7) | 62 (57.9) | 6 (46.2) | .607 |
| Rhinosinusitis, n (%) | 68 (56.7) | 59 (55.1) | 9 (69.2) | .502 |
| Recurrent pneumonia, n (%) | 65 (54.2) | 56 (52.3) | 9 (69.2) | .390 |
| Smoking status, n (%) | ||||
| Never smoker | 94 (78.3) | 85 (79.4) | 9 (69.2) | .826 |
| Active smoker | 6 (5.0) | 5 (4.7) | 1 (7.7) | |
| Ex-smoker | 15 (12.5) | 13 (12.1) | 2 (15.4) | |
| Passive smoker | 5 (4.2) | 4 (3.7) | 1 (7.7) | |
| Etiology, n (%) | ||||
| Idiopathic | 15 (12.5) | 14 (13.1) | 1 (7.7) | .239 |
| Postinfection tuberculosis | 65 (54.2) | 60 (56.1) | 5 (38.5) | |
| Postinfection nontuberculosis | 25 (20.8) | 22 (20.6) | 3 (23.1) | |
| Undetermined* | 12 (10.0) | 9 (8.4) | 3 (23.1) | |
| Kartagener syndrome | 2 (1.7) | 1 (0.9) | 1 (7.7) | |
| Primary immunodeficiency | 1 (0.8) | 1 (0.9) | 0 (0.0) | |
| Affected lobes, n (%) | ||||
| One lobe | 21 (17.5) | 21 (19.6) | 0 (0.0) | .170 |
| ≥ 2 lobes | 99 (82.5) | 86 (80.4) | 13 (100.0) | |
| Colonization Pseudomonas aeruginosa, n (%) | 22 (18.3) | 19 (17.8) | 3 (23.1) | .929 |
| Colonization others microorganisms†, n (%) | 16 (13.3) | 15 (14.0) | 1 (7.7) | .840 |
| Baseline PFT, n | 100 | 89 | 11 | |
| FEV1 (% predicted), median (IQR) | 53.35 (35.17) | 56.00 (36.90) | 34.40 (17.95) | .023 |
| FVC (% predicted), median (IQR) | 66.40 (29.38) | 69.00 (29.20) | 50.90 (16.45) | .025 |
| FEV1/FVC ratio (%), median (IQR) | 79.55 (24.92) | 82.50 (23.50) | 66.20 (17.20) | .024 |
BMI = body mass index; COPD = chronic obstructive pulmonary disease; FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; GERD = gastroesophageal reflux disease; IQR = interquartile range; n = number of patients (percentage); PFT = pulmonary functional test.
*
Undetermined: cases in etiological investigation.
†
Staphylococcus aureus, Haemophilus spp., Aspergillus flavus and nontuberculous mycobacteriosis. Obs. Analyzed with the Mann–Whitney U test for continuous variables and the chi-square test for categorical variables.